REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

By /

Organon & Co. & Samsung Bioepis Co., Ltd. announced that HADLIMA™, a biosimilar referencing Humira, is now available to patients in the United States.

Scroll to Top